Arrowhead Pharmaceuticals (ARWR) has secured a new partnership with Sarepta Therapeutics (SRPT). Under the terms of the deal, ...

Analyst Kostas Biliouris of BMO Capital reiterated a Buy rating on Sarepta Therapeutics (SRPT – Research Report), retaining the price target of ...

Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $168.79, a high estimate of ...

Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...

Oppenheimer analyst Andreas Argyrides maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...

Sarepta Therapeutics and Arrowhead Pharmaceuticals said they have entered a licensing and collaboration agreement worth more than $1 billion.

Fintel reports that on November 25, 2024, HC Wainwright & Co. initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with ...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global ...

Sarepta Therapeutics said Tuesday that it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of ...

Arrowhead Pharmaceuticals (ARWR) stock surges 21% in premarket after $825M licensing deal with Sarepta (SRPT) for rare ...

马萨诸塞州剑桥 - Sarepta Therapeutics, Inc. (NASDAQ:SRPT)与Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)签订了一项全球许可协议,获得了一系列针对肌肉、中枢神经系统 ...

Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta ...